Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Winrevair (sotatercept by Year
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — International sales ($M) ($M)
Merck Winrevair (sotatercept: $85M in FY2025, up 672.7% from a year earlier.
Where the FY2025 figure comes from
“|| Winrevair | 1,443 | 419 | * | 1,358 | 408 | * | 85 | 11 | *”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 85 | +672.7% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 11 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-25) ↗ |
Cite this data
StockData. (2026). Merck Winrevair (sotatercept ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-winrevair-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.